![Christopher Burns](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Burns
Direttore Tecnico/Scientifico/R&S presso Protez Pharmaceuticals, Inc.
Profilo
Christopher J.
Burns was the founder of Venatorx Pharmaceuticals, Inc. (founded in 2010) where he held the title of President, Chief Executive Officer & Director from 2010 to 2024.
He is currently working as Vice President-Research at Protez Pharmaceuticals, Inc. Dr. Burns previously worked as Head-Chemistry Department at Shire ViroPharma, Inc. He obtained a doctorate degree from Massachusetts Institute of Technology.
Posizioni attive di Christopher Burns
Società | Posizione | Inizio |
---|---|---|
Protez Pharmaceuticals, Inc.
![]() Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Direttore Tecnico/Scientifico/R&S | - |
Precedenti posizioni note di Christopher Burns
Società | Posizione | Fine |
---|---|---|
Venatorx Pharmaceuticals, Inc.
![]() Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Fondatore | 16/05/2024 |
Shire ViroPharma, Inc.
![]() Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Corporate Officer/Principal | - |
Formazione di Christopher Burns
Massachusetts Institute of Technology | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Protez Pharmaceuticals, Inc.
![]() Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Health Technology |
Shire ViroPharma, Inc.
![]() Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
Venatorx Pharmaceuticals, Inc.
![]() Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Commercial Services |
- Borsa valori
- Insiders
- Christopher Burns